Department of Public Health, Ümraniye District Health Directorate, Istanbul, 34764, Türkiye.
Epidemiology Program, Institute of Health Sciences, Istanbul Medipol University, Istanbul, 34815, Türkiye.
BMC Infect Dis. 2024 Jun 8;24(1):570. doi: 10.1186/s12879-024-09460-4.
It is aimed to examine the frequency of COVID-19 disease, the rates of COVID-19 vaccination and the vaccine effectiveness (VE) among Syrian refugees. It is a retrospective cohort study. Syrian refugees aged 18 years and above registered to a family health center in Sultanbeyli district in Istanbul were included. Vaccine effectiveness were calculated for both Pfizer BioN-Tech and CoronaVac (Sinovac) vaccines. The data of 2586 Syrian people was evaluated in the study. The median age of the participants was 34.0 years (min:18.0; max: 90.0). Of the participants 58.4% (n = 1510) were female, 41.6% (n = 1076) were male. In our study of the refugees 15.7% had history of COVID-19 infection. Refugees having full vaccination with Biontech and Sinovac have a significantly lower COVID-19 infection rate than those without vaccination (HR = 8.687; p < 0.001). Adjusted VE for Biontech, Sinovac, and both were 89.2% (95.0% CI:83.3-93.1), 81.2% (95.0% CI:48.72-93.1) and 88.5% (95.0% CI:82.7-92.3), respectively. The results of the study highlight the importance of vaccinations against COVID-19 pandemic, since both vaccines were highly protective in refugees.
本研究旨在调查 COVID-19 疾病的频率、COVID-19 疫苗接种率以及疫苗有效性（VE）在叙利亚难民中的情况。这是一项回顾性队列研究。研究纳入了在伊斯坦布尔苏丹贝伊利区的家庭健康中心注册的年龄在 18 岁及以上的叙利亚难民。计算了辉瑞 BioN-Tech 和科兴（Sinovac）疫苗的疫苗有效性。本研究共评估了 2586 名叙利亚人的数据。参与者的中位年龄为 34.0 岁（最小值：18.0；最大值：90.0）。参与者中 58.4%（n=1510）为女性，41.6%（n=1076）为男性。在我们对难民的研究中，有 15.7%的人有 COVID-19 感染史。与未接种疫苗的难民相比，接种过 Biontech 和 Sinovac 疫苗的难民 COVID-19 感染率显著降低（HR=8.687；p<0.001）。Biontech、Sinovac 和两者的调整 VE 分别为 89.2%（95.0%CI：83.3-93.1）、81.2%（95.0%CI：48.72-93.1）和 88.5%（95.0%CI：82.7-92.3）。研究结果强调了 COVID-19 大流行疫苗接种的重要性，因为这两种疫苗在难民中都具有高度的保护作用。
